Portal vein thrombosis (PVT) consists in the partial or total occlusion of portal vein lumen or its tributaries by a thrombus [1] .
Liver cirrhosis and hepatocellular carcinoma (HCC) are the main causes of PVT [1] . A study based on postmortem examinations showed that prevalence of portal vein thrombosis was 4.5% in cirrhotic patients without HCC and 14.3% in patients with HCC [2] .
Two pathophysiological mechanisms underlie PVT. Benign thrombosis is determined by slow portal blood flow, reflecting the mechanisms underlying peripheral venous thrombosis, and it is histologically characterized by fibrin clot and absence of platelets [1] . Although once bland PVT represented an absolute contraindication for liver transplantation, recent studies have shown that between patients who had undergone transplantation those with partial benign thrombosis had not dissimilar survival rates [3] .
On the other hand malignant thrombosis derives from direct vessel wall involvement by parenchymal tumour and it is related to advanced stage of disease with very limited therapeutic chances, representing an absolute contraindication for liver transplantation [3] .
Nowadays imaging represents the most common and safe method for PVT characterization with reduced need for histopathologic proof, a procedure that carries some risks in patients with advanced liver disease.
Several imaging techniques can be employed for PVT characterization. Despite the fact that contrast-enhanced and colour Doppler ultrasonography [4e6] and magnetic resonance with diffusion-weighted imaging are reported as highly accurate techniques [7, 8] , multislice computed tomography (MSCT) is the most used imaging technique for characterization of PVT and its underlying causes [9e11] .
Conventional MSCT study protocol includes an unenhanced study for baseline density measurements in Hounsfield units (HU) and contrast-enhanced acquisition, in the arterial or venous phase, to evaluate the presence of intrathrombus enhancement, which is one of the most reliable imaging features in distinguishing between bland and neoplastic thrombus (HU contrast phase e HU unenhanced phase ) [9, 11] .
Dual-energy CT (DECT) with iodine quantification offers an alternative approach independent from attenuation measurements, based on the presence of iodine in tissues, providing a more direct measure of lesion vascularization [12, 13] .
Recent studies [14] demonstrated that DECT with iodine quantification is a highly accurate noninvasive approach for PVT characterization in patients with hepatocellular carcinoma, yielding higher sensitivity and specificity compared with conventional enhancement measurements [14] .
Another advantage of DECT is represented by the possibility of radiation dose reduction, using virtual unenhanced (VUE) instead of true unenhanced (TUE) images [15] .
To our knowledge there are no studies that compare TUE and VUE images validating their reliability in this application field.
The aim of this study was to compare DECT VUE and single-energy (SE) TUE images and to calculate the potential dose reduction by omitting the conventional unenhanced scan in PVT characterization.
Materials and Methods
The Institutional Review Board approved this retrospective study conducted from data found in our institutional patient databases and archives. Signed consent from the patients was obtained.
Patients
All cirrhotic patients and those suspected to have HCC with <35 cm abdominal diameter or weighting less than 90 kg are routinely scheduled for DECT study at our institution.
A computerized search of our hospital information system (SuitEstensa Web; Esaote Biomedica, Indianapolis, IN) for patients who underwent DECT using the following keywords: portal vein thrombosis, bland thrombus, neoplastic thrombus, dual energy CT, and hepatocellular carcinoma yielded data for 94 patients with HCC and portal vein thrombosis from September 2008 to January 2013.
Patients were excluded from this study for the following reasons: 1) lack of histopathologic proof of HCC (patients n ¼ 32); 2) PVT pathological diagnoses or reports on followup examinations were not available (n ¼ 21); 3) CT data were not available for reconstruction (n ¼ 2); 4) chronic PV occlusion with cavernous transformation precluding portal vein or thrombus identification (n ¼ 6).
Therefore, our final study cohort consisted of 33 patients (24 men, 9 women; mean age 62.4 AE 8.6 years; age range 48-79 years; mean body mass index 30.2 AE 6.9) who underwent contrast enhanced DE multidetector CT (MDCT) during late hepatic arterial phase and SE MDCT during basal and portal venous phases in the clinical setting of a histopathologically proven HCC (single nodular type, n ¼ 18; multinodular type, n ¼ 11; diffuse type, n ¼ 2; massive type, n ¼ 2).
CT Data Acquisition
All CT examinations were performed by using a dualsource CT system (Somatom Definition Dual Source; Siemens AG, Healthcare Sector, Forchheim, Germany), consisting of 2 X-ray tubes arranged on the gantry with a 90 angular offset and 2 detectors that respectively cover a 50 cm (tube A) and a 26 cm (tube B) field of view. These 2 tubes operate independently with regard to tube voltage and tube current.
Unenhanced and late hepatic arterial phases were obtained from the hepatic dome to the iliac crest, whereas portal venous phase acquisition was extended from the hepatic dome to the pubic symphysis.
Bolus tracking (CARE Bolus, Siemens Healthcare, Forchheim, Germany) technique was performed to obtain a right timing for late arterial or in-flow portal vein phase: scan has been started with a 15-second delay after arrival of the bolus in the abdominal aorta using an attenuation predefined threshold of þ100 HU above the baseline [16] . SE portal venous acquisition was performed with a fixed time delay of 80 seconds.
All patients received a nonionic contrast medium (Iomeprol, 400 mg of iodine per milliliter, Iomeron 400; Bracco Imaging, Milan, Italy) at a dose of 1.4 mL (560 mg of iodine) per kilogram of body weight. The contrast medium was warmed to 37 C and administered with a dual-chamber mechanical power injector (Stellant D CT; Medrad, Indianola, PA) at a rate of 4-5 mL/s through an intravenous catheter inserted into an antecubital vein. This was followed by a 30 mL saline flush at the same injection rate.
Scanning parameters used for SE images acquisition were: 2 Â 32 Â 0.6 mm detector collimation; 120 kVp tube voltage; 250 mAs tube current quality reference; 0.70 pitch factor; 0.5 seconds gantry rotation time.
Scanning parameters used for DE acquisition were: 14 x 1.2 mm detector collimation; tube A: voltage 140 kVp, current-time product (mAs) 95; tube B: voltage 80 kVp, current time product (mAs) 510; 0.70 pitch factor; 0.5 seconds gantry rotation time. These scanning parameters corresponded to the vendor's suggestions. All acquisitions were obtained with an automatic exposure control system (Care Dose 4D; Siemens AG).
CT Data Reconstruction
From the SE data sets, 3 mm contiguous axial unenhanced and portal venous images were reconstructed with a smooth (B31f) convolution kernel.
From the DE data sets, 3 mm contiguous axial images, which approximate the image quality (IQ) of a standard 120 kVp scan of the abdomen, were obtained with a combination of image data averaging 30% from the low-kilovoltage tube B and 70% from the high-kilovoltage tube A (M0.3), using a dedicated DE convolution kernel (D30f).
All images were stored in a secondary workstation (Syngo Dual Energy version MMWP 2010A, Siemens AG).
DE postprocessing was performed using the Liver Virtual Non-Contrast application (Liver VNC; Siemens AG, Healthcare Sector, Forchheim, Germany) as an image-based analysis of the low-and high-energy kVp images. This software works with a 3-material decomposition algorithm that uses attenuation changes of soft tissue, fat, and iodine at different peak voltages. Assuming that every voxel in the abdomen is composed of fat, soft tissue, and iodine, the algorithm generates a map that encodes the iodine distribution in each voxel.
In each case the manufacturer default values for soft tissue and fat attenuation at 80 and 140 kVp were replaced by the patient's specific attenuation values, obtained by placing a large region of interest (ROI) over the paraspinal muscles and adjacent subcutaneous fat on both the 80 and 140 kVp datasets. Both these measurements were obtained at the level of the main portal vein.
Iodine was overlaid with 50% iodine overlay display to obtain colour-coded iodine overlay maps and was completely subtracted to obtain virtual unenhanced images [17, 18] .
For both data sets 3-mm-thick axial images were reconstructed.
CT Image Analysis
Two experienced abdominal radiologists, on consensus, evaluated SE unenhanced and portal venous images and DE colour-coded images. The readers were asked to identify and localize PVT and to measure portal vein calibre at the same level.
For each image data set reviewers positioned ROI in the sections in which thrombus was most evident and enhancement was suspected, using the copy-and-paste function, in order to maintain the same ROI area (two-thirds of the area of the thrombus at least), taking care to exclude the vessel wall. For each thrombus circular ROIs were drawn 5 times: the mean CT numbers were obtained using average values from 3 ROI measurements after excluding the higher and the lower values.
Mean attenuation and standard deviation of thrombi were recorded.
Liver VNC ROI tool display includes mean, standard deviation, minimum, and maximum attenuation values in HU of virtual unenhanced images and corresponding contrast enhancement in HU (ie, Overlay).
Arterial thrombus attenuation in HU using DE images was obtained summing VNC and Overlay values.
All data were plotted on an excel worksheet for analysis.
CT Image Quality
Two independent, experienced abdominal radiologists, in separate reading sessions, analysed on a dedicated workstation (Syngo Dual Energy, version MMWP 2010A; Siemens AG), TUE and VUE images displayed side by side on 2 different screens.
As images can be easily discriminated, radiologists were not blinded as to which images represented the TUE and VUE dataset. A 5-point grading scale was used to score the IQ of portal thrombus on TUE and VUE images: 1 ¼ excellent quality with no artifacts (no perceivable artifact); 2 ¼ good quality with minor artifacts (slight artifact without interfering with diagnostic capability); 3 ¼ fair quality with moderate artifacts (artifact degrading the diagnostic capability); 4 ¼ poor quality with major artifacts (artifact lowering to minimum the diagnostic capability); 5 ¼ image not interpretable due to presence of severe artifacts (artifact resulting in the loss of diagnostic capability).
Interobserver agreement for IQ evaluation was assessed.
Reference Standard
The 33 enrolled patients had a total of 39 thrombi. Histopathology was available for 7 patients, each of which had a single thrombus. Reference standard for the 26 patients with no histopathologic proof was follow-up CT evaluation with mean duration of 24 months (AE6 SD; range 12-36 months). An increase in portal vein diameter >30% was considered suggestive of malignant PVT, while stable or reduced thrombus size was considered indicative of benignity.
Radiation Doses
The mean estimated CT dose index and dose-length product (DLP) for unenhanced and portal venous phases SE acquisitions and for arterial phase DE acquisition were recorded.
Effective radiation doses (in milliSieverts) were calculated for each phase by using the method proposed by the European Working Group for Guidelines on Quality Criteria in CT, applying the following relationship: E ¼ DLP Â k conversion coefficient, where the abdominal k conversion coefficient is 0.015 mSv/mGy cm [19, 20] .
The effective dose of a combined DE/SE protocol (DE hepatic late arterial þ SE portal venous phase) was compared with that of a theoretical standard SE protocol (unenhanced, late arterial, and portal venous phases) obtained by doubling the recorded dose for unenhanced phase and summing it with recorded portal venous phase dose.
Statistical Analysis
Numerical values of continuous variables are expressed as mean AE SD, and categorical variables are expressed as frequencies or percentages.
Measured CT numbers were tested for normal distribution by using 1-sample Kolomogorov-Smirnov test.
Thrombus mean contrast enhancement measured on venous and DE arterial images as well as attenuation values on TUE and VUE colour-coded iodine overlay images were tested for statistical significance by paired Student's t test.
The Cohen's k statistic was used to assess the interobserver agreement during the IQ session. The guidelines of Landis and Koch were followed to interpret k values: 0.00-0.20 indicated slight agreement; 0.21-0.40, fair agreement; 0.41-0.60, moderate agreement; 0.61-0.80, substantial agreement, 0.80-1.00, almost perfect agreement. The Wilcoxon signed rank test was used to compare mean TUE and VUE IQ scores.
Effective radiation doses for combined DE/SE dual-phase and SE triple-phase protocols were calculated, and results were tested for statistical significance by using the paired t-test. P values <.05 were considered to indicate statistically significant differences.
All statistical analyses were performed by using statistical software (MedCalc, version 12.7.1.0; MedCalc, Mariakerke, Belgium).
Results

Patients
Thirty-nine portal thrombi (15 malignant and 24 benign) were recognized in 33 patients.
Six patients had 2 different thrombi in separate branches of the portal vein (2 patients had 2 benign thrombi; 3 patients had 2 neoplastic thrombi; 1 patient had both neoplastic and benign thrombi).
Mean portal vein was 1.94 AE 0.68 cm (range 1.2-3.2 cm) for neoplastic thrombi and 1.68 AE 0.61 cm (range 0.7-3 cm) for bland thrombi. 
Image Analysis
CT Image Quality
Using a 5-point grading system no statistically significant difference (P > .05) was found between the mean TUE and VUE IQ.
No image was judged as not interpretable due to presence of severe artifacts (score 5).
Mean score assigned by both readers are summarized in Table 2 .
Reader 1 assigned a mean score of 1.48 and 1.66 to TUE and VUE images, respectively.
Reader 2 assigned a mean score of 1.57 and 1.72 to TUE and VUE images, respectively. The Cohen's k test showed an almost perfect agreement between Reader 1 and Reader 2 (k >0.80 for both TUE and VUE series) for IQ assessment.
Radiation Doses
Measured mean effective doses were 3.8 AE 1.6 mSv (range 2.1-7.2 mSv) for the SE unenhanced phase, 6.8 AE 2.3 mSv (range 3.7-12.4 mSv) for the SE venous phase, and 4.8 AE 1.9 (range 2.8-8.5 mSv) for the DE late arterial hepatic phase. For the combined DE/SE protocol, the mean effective dose was 11.6 AE 2.4 mSv (range 6.8-15.2 mSv), whereas the theoretical standard SE protocol delivered a mean effective dose of 15.4 AE 3.1 mSv (range 8.4-21.1 mSv), assuming that the dose for a single-phase arterial acquisition would be the same as for the unenhanced acquisition. The calculated mean dose reduction achievable by omitting the unenhanced scan was 24.7% (P < .001).
Discussion
Despite advances in US and MR imaging in the diagnosis of PVT [4e8], MSCT remains the most widely used imaging approach in characterization of thrombus nature in patients affected by cirrhosis and HCC [7, 11, 14, 21] .
In these patients multiphasic approach is mandatory for the evaluation of thrombus enhancement that represents the most accurate conventional CT parameter in the characterization of PVT, with sensitivity and specificity respectively of 82% and 100% [11] . On conventional CT unenhanced study is fundamental for determining thrombus baseline attenuation, while venous phase is the most accurate for thrombus detection because, during late arterial phase, neoplastic thrombus vascularity could sometimes mimic the initial inflow of iodinated blood into the portal circulation preventing radiologists from detecting thrombus.
On the other hand arterial phase is paramount in order to detect the purely arterial enhancement behavior of neoplastic thrombosis, similar to the primary lesion, and to depict the presence of HCC and possible portal vein direct involvement, that represents another accurate conventional CT feature in the characterization of PVT (Figure 1) [11] .
By now DECT represents a strengthened approach for liver imaging.
For cirrhotic patients, the use of DE acquisition during late arterial phase has the main advantage of high contrast resolution of hypervascular lesions using both virtual monochromatic and non-linear blending mode images. These software allow to preserve IQ while amplifying iodine signal [22e24].
DECT overcomes many of the problems related to multiphase acquisitions because a single ROI placed on DE colour-coded iodine overlay image shows baseline attenuation and enhancement in HU [15, 17, 18] . Using this approach, TUE could be replaced by VUE scan images and further consistent advantages could be represented by radiation dose lowering and examination time reduction, as demonstrated in other fields of abdominal radiology [15, 20, 25] .
Our data show not significant difference of attenuation values of portal vein thrombi between TUE and VUE images (P ¼ .48).
Despite this, 6 patients (18%) of our series showed attenuation value differences between TUE and VUE >10 HU. In 5 of 6 cases we found slight attenuation differences (between 10-19 HU) that we were not able to explain. In the remaining patient with a long-standing calcified thrombus, we found a greater (26 HU) lack of correspondence of HU numbers between VUE and TUE. In this patient DE software wrongly recognized calcium as iodine and, subtracting it from image data, determined an erroneously lower attenuation value of thrombus on baseline evaluation, leading to a false positive diagnosis of neoplastic thrombosis. However, the clear detectability of the coarse thrombus calcification on VUE images, allowed to avoid this diagnostic error (Figure 2 ).
Most recently, DECT allows direct quantification of the iodine uptake (in mg/mL) in a tissue [12, 13, 26] . This alternative approach, independent from attenuation measurements, rather than a change in enhancement depicts the amount of iodine in tissues, providing a more straightforward evaluation of lesion vascularity [12, 13] .
Accuracy of DECT with iodine quantification has been recently investigated by Qian et al [14] . Using a single- source DECT platform on portal venous phase the authors obtained sensitivity and specificity of 100% and 91.7%, respectively, with the threshold of 1.14 mg/mL.
With the advent of iodine quantification tool we can witness a paradigm shift from a mere attenuation change evaluation to a mostly quantitative analysis; thus IQ rather than strict quantitative assessment of HU, is the main issue to consider for routinely use of VUE instead of TUE images.
Comparing VUE and TUE images in patients suspected of having renal masses, Graser et al [15] concluded that VUE images closely resemble TUE images showing good IQ, even though not superior to TUE images, obtaining a radiation dose reduction of 35.05%.
De Cecco et al [25] evaluated liver images IQ in 40 patients and concluded that no statistically significant difference was found in mean TUE and VUE IQ in liver imaging, obtaining a radiation dose reduction of 30.47%.
Mileto et al [20] , in 51 patients with known or suspected pancreatic masses, showed no significant differences between IQ in VUE and TUE images and a dose reduction of 26,70% using a combined DE/SE dual-phase protocol.
Our results confirmed an elevated IQ of the VUE even though inferior compared with TUE. Reviewer 1 and 2 assigned score 1 (excellent quality) and score 2 (good quality) at VUE in 93% and 90.9% of patients with respect to 96.6% and 93.9% of TUE images.
In 2 cases of our series in which VUE IQ was evaluated as poor (score 4) by the reviewers, subtle and thin calcifications of hepatic parenchyma and aortic wall were considered as iodine and erroneously subtracted by the DE algorithm ( Figure 1 ). Partial subtraction of calcification or plastic biliary prosthesis was reported in a previous study [20] and similar issues related to small sized urinary stones missing have been reported in DE urologic imaging [27] .
Subtraction of calcium from DECT data represents an inherent technical limitation of the VNC algorithm because calcium is not among the analysed materials of the 3-material-decomposition algorithm (fat, soft tissue, and iodine).
In hepatic imaging this problem could be overcome by using another postprocessing algorithm that analyses calcium, iodine, and soft tissue as hard plaque imaging algorithm.
Radiation dose reduction could represent an advantage for young cirrhotic patients who need CT follow-up for many years. Our results demonstrate that the use of a combined DE/SE dual-phase protocol, significantly (P < .001) allows to reach a radiation dose saving up to 24.7% compared with a standard SE triple-phase protocol.
Weaknesses of our study must be acknowledged. First of all, in our series no thrombi with tiny or subtle calcifications were found. Consequently we do not know if small amounts of calcium could simulate artifactual iodine presence; thus further studies with larger cohorts of patients are necessary.
Moreover, despite the retrospective design of this study, a potential criticism could be the choice of CT follow-up imaging as a reference standard in all cases in which histopathologic proof was not available. However, despite followup represents the common standard of references for cirrhotic patients, diagnostic accuracy of DECT in the characterization of PVT nature was not the aim of this study.
Finally, according to the vendor's recommendations and clinical experience, patients with 35 cm or major abdominal diameter or weighting more than 90 kg were excluded from DECT study at our institution. However, the role of abdominal DECT in patients with body mass index >30 kg/ m 2 still remains to be clarified and further studies need to be performed to evaluate whether iodine quantification provides accurate information over a broad spectrum of patients with various body habitus.
In conclusion our results demonstrated that VUE images represent an alternative to conventional TUE images, obviating the need for standard unenhanced imaging in PVT characterization with a significant lowering of radiation dose.
